BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abutaleb NS, Seleem MN. Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections. Antimicrob Agents Chemother 2020;64:e02115-19. [PMID: 32253206 DOI: 10.1128/AAC.02115-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Abutaleb NS, Elhassanny AE, Seleem MN. In vivo efficacy of acetazolamide in a mouse model of Neisseria gonorrhoeae infection. Microbial Pathogenesis 2022. [DOI: 10.1016/j.micpath.2022.105454] [Reference Citation Analysis]
2 Rollin-Pinheiro R, Borba-Santos LP, da Silva Xisto MID, de Castro-Almeida Y, Rochetti VP, Rozental S, Barreto-Bergter E. Identification of Promising Antifungal Drugs against Scedosporium and Lomentospora Species after Screening of Pathogen Box Library. J Fungi (Basel) 2021;7:803. [PMID: 34682224 DOI: 10.3390/jof7100803] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen J, Li Y, Wang S, Zhang H, Du Y, Wu Q, Wang H. Targeting Clostridioides difficile: new uses for old drugs. Drug Discov Today 2022:S1359-6446(22)00131-3. [PMID: 35390545 DOI: 10.1016/j.drudis.2022.03.021] [Reference Citation Analysis]
4 Abutaleb NS, Seleem MN. In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Sci Rep 2021;11:7093. [PMID: 33782498 DOI: 10.1038/s41598-021-86595-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hewitt CS, Abutaleb NS, Elhassanny AEM, Nocentini A, Cao X, Amos DP, Youse MS, Holly KJ, Marapaka AK, An W, Kaur J, Krabill AD, Elkashif A, Elgammal Y, Graboski AL, Supuran CT, Seleem MN, Flaherty DP. Structure-Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae. ACS Infect Dis 2021;7:1969-84. [PMID: 33765392 DOI: 10.1021/acsinfecdis.1c00055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Abutaleb NS, Elhassanny AEM, Nocentini A, Hewitt CS, Elkashif A, Cooper BR, Supuran CT, Seleem MN, Flaherty DP. Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae. J Enzyme Inhib Med Chem 2022;37:51-61. [PMID: 34894972 DOI: 10.1080/14756366.2021.1991336] [Reference Citation Analysis]
7 Naclerio GA, Abutaleb NS, Alhashimi M, Seleem MN, Sintim HO. N-(1,3,4-Oxadiazol-2-yl)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae. Int J Mol Sci 2021;22:2427. [PMID: 33671065 DOI: 10.3390/ijms22052427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
9 Pal R, Dai M, Seleem MN. High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitro. Sci Rep 2021;11:10913. [PMID: 34035338 DOI: 10.1038/s41598-021-90314-3] [Reference Citation Analysis]
10 Abutaleb NS, Elhassanny AEM, Flaherty DP, Seleem MN. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ 2021;9:e11059. [PMID: 33850651 DOI: 10.7717/peerj.11059] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN. In Vivo Antibacterial Activity of Acetazolamide. Antimicrob Agents Chemother 2021;65:e01715-20. [PMID: 33495225 DOI: 10.1128/AAC.01715-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]